AU Patent

AU2024329780A1 — Elafibranor for use in the treatment of primary biliary cholangitis

Assigned to Ipsen Pharma SAS · Expires 2026-03-26 · 0y expired

What this patent protects

The present invention concerns elafibranor for use for the treatment of Primary Biliary Cholangitis (PBC) in a subject with PBC and with liver cirrhosis, and preferably a subject having Child-Pugh score A or having Child-Pugh score B.

USPTO Abstract

The present invention concerns elafibranor for use for the treatment of Primary Biliary Cholangitis (PBC) in a subject with PBC and with liver cirrhosis, and preferably a subject having Child-Pugh score A or having Child-Pugh score B.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024329780A1
Jurisdiction
AU
Classification
—
Expires
2026-03-26
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Pharma SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.